BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25518744)

  • 1. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
    Beall RF; Kuhn R; Attaran A
    Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
    Zapatero Miguel P
    Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.
    Qunaj L; Kaltenboeck A; Bach PB
    Milbank Q; 2022 Mar; 100(1):284-313. PubMed ID: 35257415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines.
    Son KB; Lee TJ
    Glob Public Health; 2018 Oct; 13(10):1430-1440. PubMed ID: 29183271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cautionary Notes on a Global Tiered Pricing Framework for Medicines.
    Williams OD; Ooms G; Hill PS
    Am J Public Health; 2015 Jul; 105(7):1290-3. PubMed ID: 25973806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WTO approves TRIPS amendment on importing under compulsory licensing.
    Herget G
    HIV AIDS Policy Law Rev; 2006 Apr; 11(1):23-4. PubMed ID: 16805011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic justification for open access to essential medicine patents in developing countries.
    Flynn S; Hollis A; Palmedo M
    J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to critical medicines: When are compulsory licenses effective in price negotiations?
    Ramani SV; Urias E
    Soc Sci Med; 2015 Jun; 135():75-83. PubMed ID: 25957163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.